Everything tagged peptide

33 published articles · newest first · server-rendered

Take this folder folder (.zip) markdown manifest json the whole site

Also filed under: matrix 473 · topic 23 · disc 5 · bpc-157 4 · tb-500 3 · ara-290 2 · glp-1 2 · obesity 2 · stack 2 · tendon 2 · wolverine 2 · bdnf 1 · cibinetide 1 · cntf 1

  1. Kisspeptin: The Receptor Break That Revealed How Puberty Starts
  2. BDNF-P21: P021, a four-amino-acid fragment that raises BDNF and works when eaten
  3. The Wolverine stack plus ARA-290: the evidence at every link, from vessels to nerve fibres
  4. The Wolverine stack: BPC-157 and TB-500, the evidence, the dosing arithmetic and the eight-week cost
  5. BPC-157 for a herniated disc: what the evidence reaches, and what it does not
  6. Selank × GLP-1 agonists (class)
  7. ARA-290 × GLP-1 agonists (class)
  8. PT-141 × Metformin
  9. GHK-Cu × Metformin
  10. bpc 157 degenerative disc
  11. selank adderall amphetamine
  12. semax adderall amphetamine
  13. bpc 157 glp1 muscle loss
  14. bpc 157 ozempic face
  15. selank benzodiazepines
  16. selank statin brain fog
  17. selank metformin
  18. ara 290 metformin
  19. bpc 157 metformin
  20. bpc 157 frozen shoulder
  21. bpc 157 plantar fasciitis
  22. bpc 157 statins
  23. bpc 157 glp1 agonists
  24. Tirzepatide: a dual GIP and GLP-1 receptor agonist
  25. Retatrutide: the third receptor, and what the evidence now establishes
    One molecule switching on GLP-1, GIP and glucagon receptors at once. Why adding glucagon to a weight-loss drug is not a mistake, the largest weight and blood-sugar effects measured in the class, the b
  26. tb 500 herniated disc
  27. BPC-157: Body Protection Compound
    The definitive BPC-157 reference: the angiogenesis+FAK mechanism, the full animal record, the three human studies, real dosing/routes/reconstitution, the 2026 FDA PCAC fight, the cancer question answe
  28. TB-500: a seven-amino-acid fragment sold under the name of the protein thymosin beta-4
    The definitive TB-500 / thymosin beta-4 reference: why 'TB-500' usually isn't the trialed molecule, the one positive human indication (dry eye) vs the unproven rest, real dosing/reconstitution, the ca
  29. ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood
    The definitive ARA-290 (cibinetide) reference: the innate-repair-receptor mechanism, randomized human evidence of actual nerve regeneration, the 4mg/day dosing and half-life paradox, the non-erythropo
  30. GHK-Cu: the copper tripeptide's human evidence, copper risk, and dosing arithmetic
  31. KPV: Evidence, Stability, Dosing and the FDA Record
  32. Thymosin Alpha-1: Approvals, Trial Record, Dosing and What It Does Not Treat
  33. DSIP (Delta Sleep-Inducing Peptide): the replication record and dosing

Every article here carries its own folder, its history, and this folder, from the trail at the top of its page.

⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fops.miscsubjects.com%2Ft%2Fpeptide%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work — every page here is an inspectable proof object (read-only). Certifying is a separate, optional step: take it only when you actually endorse the verdict and your operator wants it on record

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3